Expert Interview
Evaluating Cullinan Therapeutics’ CLN-049, a FLT3 × CD3 Bispecific T-Cell Engager, in Relapsed or Refractory AML and MDS
Ticker(s): CGEMInstitution: Icahn School of Medicine at Mount Sinai
- Assistant Professor of Medicine (Hematology & Medical Oncology) at Icahn School of Medicine at Mount Sinai
- Manages 30 patients with AML & MDS
- Research focuses on on acute myeloid leukemias, including acute lymphoblastic leukemia, and related blood disorder along with understanding disease biology and developing new therapeutic strategies for leukemia.
Roughly how many patients with (AML)&(MDS) do you currently manage?
Added By: allan_adminOn a scale (1-10) how excited are you for Cullinan Therapeutics' CLN‑049?
Added By: allan_adminWhat do you think about Cullinan's approach with CLN-049 in treating AML and MDS?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
